breast cancer elderli women cancer research campaign trial treatment tamoxifen optim surgeri tamoxifen elderli breast cancer work parti eighty-on women oper breast cancer year mg tamoxifen daili optim surgeri median follow-up month demonstr differ surviv rate qualiti life treatment group patient tamoxifen subsequ chang manag oper local treatment failur progress surgeri disadvantag studi inform consent random difficult exclus elig patient non-random patient total cohort studi 